References
- Ali R, Mirza Z, Ashraf GM, et al (2012). New anticancer agents: recent developments in tumor therapy. Anticancer Res, 32, 2999-3005.
- Butthongkomvong K, Sirachainan E, Jhankumpha S, Kumdang S, Sukhontharot OU (2013). Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev, 14, 3565-8. https://doi.org/10.7314/APJCP.2013.14.6.3565
- Czabotar PE, Lessene G, Strasser A, Adams JM (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol, 15, 49-63. https://doi.org/10.1038/nrm3722
- Dokduang H, Juntana S, Techasen A, et al (2013). Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol, 34, 3519-28. https://doi.org/10.1007/s13277-013-0930-9
- George VC, Naveen Kumar DR, Suresh PK, Kumar S, Kumar RA (2013). Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac J Cancer Prev, 14, 631-7. https://doi.org/10.7314/APJCP.2013.14.2.631
- Hagedorn EJ, Sherwood DR (2011). Cell invasion through basement membrane: the anchor cell breaches the barrier. Curr Opin Cell Biol, 23, 589-96. https://doi.org/10.1016/j.ceb.2011.05.002
- Hu L, Wu QQ, Wang WB, et al (2013). Suppression of Ku80 correlates with radiosensitivity and telomere shortening in the U2OS telomerase-negative osteosarcoma cell line. Asian Pac J Cancer Prev, 14, 795-9. https://doi.org/10.7314/APJCP.2013.14.2.795
- Hwang JT, Park OJ, Lee YK, et al (2011). Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-kappaB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med, 28, 25-31.
- Isomoto H (2009). Epigenetic alterations in cholangiocarcinomasustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Digestion, 79, 2-8. https://doi.org/10.1159/000167859
- Lavecchia A, Di Giovanni C, Novellino E (2012). CDC25 phosphatase inhibitors: an update. Mini Rev Med Chem, 12, 62-73. https://doi.org/10.2174/138955712798868940
- Lee EJ, Oh SY, Sung MK (2012). Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol, 50, 4136-43. https://doi.org/10.1016/j.fct.2012.08.025
- Lim S, Kaldis P (2013). Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 140, 3079-93. https://doi.org/10.1242/dev.091744
- Lopez-Lazaro M (2009). Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 9, 31-59. https://doi.org/10.2174/138955709787001712
- Mihalache F, Tantau M, Diaconu B, Acalovschi M (2010). Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis, 19, 285-90.
- Pandurangan AK, Dharmalingam P, Sadagopan SK, et al (2013). Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/beta-Catenin/GSK-3beta signaling. J Environ Pathol Toxicol Oncol, 32, 131-9. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2013007522
- Patel V, Senderowicz AM, Pinto D, et al (1998). Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest, 102, 1674-81. https://doi.org/10.1172/JCI3661
- Prakobwong S, Khoontawad J, Yongvanit P, et al (2011). Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer, 129, 88-100. https://doi.org/10.1002/ijc.25656
- Pratheeshkumar P, Son YO, Budhraja A, et al (2012). Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One, 7, 52279. https://doi.org/10.1371/journal.pone.0052279
- Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V (2009). Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol, 135, 515-22. https://doi.org/10.1007/s00432-008-0483-2
- Ruan JS, Liu YP, Zhang L, et al (2012). Luteolin reduces the invasive potential of malignant melanoma cells by targeting beta3 integrin and the epithelial-mesenchymal transition. Acta Pharmacol Sin, 33, 1325-31. https://doi.org/10.1038/aps.2012.93
- Sankari SL, Masthan KM, Babu NA, Bhattacharjee T, Elumalai M (2012). Apoptosis in cancer--an update. Asian Pac J Cancer Prev, 13, 4873-8. https://doi.org/10.7314/APJCP.2012.13.10.4873
- Selvendiran K, Koga H, Ueno T, et al (2006). Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res, 66, 4826-34. https://doi.org/10.1158/0008-5472.CAN-05-4062
- Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U (2013). Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via Suppression of JAK/STAT Signaling Pathway. Phytother Res, 28, 841-8.
- Sripa B, Brindley PJ, Mulvenna J, et al (2012). The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol, 28, 395-407. https://doi.org/10.1016/j.pt.2012.07.006
- Suphim B, Prawan A, Kukongviriyapan U, et al (2010). Redox modulation and human bile duct cancer inhibition by curcumin. Food Chem Toxicol, 48, 2265-72. https://doi.org/10.1016/j.fct.2010.05.059
- Wang TT, Wang SK, Huang GL, Sun GJ (2012). Luteolin induced-growth inhibition and apoptosis of human esophageal squamous carcinoma cell line Eca109 cells in vitro. Asian Pac J Cancer Prev, 13, 5455-61. https://doi.org/10.7314/APJCP.2012.13.11.5455
- Zhao X, Sun X, Li XL (2012). Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev, 13, 2873-7. https://doi.org/10.7314/APJCP.2012.13.6.2873
Cited by
- Rutin mediated targeting of signaling machinery in cancer cells vol.14, pp.1, 2014, https://doi.org/10.1186/s12935-014-0124-6
- Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0134793
- Current Insights on Cholangiocarcinoma Research: a Brief Review vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1307
- Inflammation and Cancer Development in Pancreatic and Biliary Tract Cancer vol.66, pp.6, 2015, https://doi.org/10.4166/kjg.2015.66.6.325
- Hedyotis�diffusa Willd. extract suppresses proliferation and induces apoptosis via IL-6-inducible STAT3 pathway inactivation in human colorectal cancer cells pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.2956
- Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-5015-0
- STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma vol.43, pp.3, 2016, https://doi.org/10.1002/biof.1345
- and TPGS vol.68, pp.10, 2016, https://doi.org/10.1111/jphp.12598
- Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle-delivered short hairpin RNAs against Stat3 vol.16, pp.1, 2017, https://doi.org/10.3892/mmr.2017.6583
- Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation vol.8, pp.1, 2017, https://doi.org/10.1039/C6FO01529H
- Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells vol.13, pp.6, 2017, https://doi.org/10.3892/ol.2017.5951
- Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway vol.19, pp.6, 2018, https://doi.org/10.3390/ijms19061567